Statin treatment tied to moderately lower COVID-19 mortality in large population study accounting for preexisting health conditions and other factors
MONDAY, Oct. 25, 2021 (HealthDay News) — Preexisting statin treatment is associated with slightly lower COVID-19 mortality, according to a study published online Oct. 14 in PLOS Medicine.
Rita Bergqvist, from the Karolinska Institutet in Stockholm, and colleagues assessed the relationship between statin treatment initiated before the pandemic and COVID-19 mortality among 963,876 Stockholm residents (ages 45 years or older).
The researchers reported that 17.6 percent of the patients in the cohort were statin users. COVID-19-related deaths occurred in 0.5 percent of the statin users and 0.2 percent of nonusers. In an adjusted analysis, statin treatment was associated with lowered COVID-19 mortality (adjusted hazard ratio, 0.88). This association remained consistent across age groups, sexes, and COVID-19 risk groups.
“Our findings support the continued use of statins for conditions such as cardiovascular disease and high levels of blood lipids in line with current recommendations during the COVID-19 pandemic,” a coauthor said in a statement.
One author disclosed financial ties to the pharmaceutical industry.
87.5 Million U.S. Adults Now Eligible for Statins Under New Guidelines 
For Most People, Risk for Serious Muscle Disorders From Statins Is Low 
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Meta-Analysis Identifies Few Adverse Events Attributed to Statin Use 
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia .jpg)
Health Consequences Vary by Chemo Regimen in Testicular Cancer Survivors 
Satisfaction With Semaglutide Driven by Effective Weight Loss 
Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer 
